Multiple epidemiological studies on the distribution of ALK mutations in relation to MYCN status and other genomic parameters have revealed the co-occurrence of ALK mutations and MYCN amplification in neuroblastoma (Bagci et al., 2012; De Brouwer et al., 2010), indicating that additional oncogenic drivers exist other than ALK. Here, ALK is linked to neuroblastoma.